Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) is a commercial-stage biopharmaceutical company developing and commercializing cancer therapies. Its two FDA-approved medicines are Revuforj (revumenib), an oral menin inhibitor for certain forms of relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a… From the company’s description.
Over the twelve months to Sep 30, 2026, Syndax Pharmaceuticals Inc reported revenue of $289.68M, up 160.3% from a year earlier, and a net loss of $209.48M. Its operating margin was −61.7%, and operations used $177.36M in cash. In fiscal 2025, it reported revenue of $172.35M, up 627.8% from fiscal 2024, and a net loss of $285.42M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Syndax Pharmaceuticals Inc does
In the company’s own words
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) is a commercial-stage biopharmaceutical company developing and commercializing cancer therapies. Its two FDA-approved medicines are Revuforj (revumenib), an oral menin inhibitor for certain forms of relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a CSF-1R-blocking antibody for chronic graft-versus-host disease after at least two prior systemic therapies. Syndax leads U.S. commercialization and development of Revuforj and co-commercializes Niktimvo in the United States with Incyte, which leads its global commercialization. Development programs include studying revumenib in combinations for acute leukemia and axatilimab in earlier-line chronic graft-versus-host disease and idiopathic pulmonary fibrosis. The company also holds a license for entinostat, a deprioritized cancer drug candidate approved for marketing in China. It licenses its medicines from other companies and relies on contract manufacturers and partners for product supply. Syndax reported 2025 revenue of $[amount not provided]. Its website is [URL not provided].
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1395937
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Syndax Pharmaceuticals Inc — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Syndax Pharmaceuticals Inc’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Syndax Pharmaceuticals Inc’s bonds, as funds hold them
Funds report holding 1 issues of Syndax Pharmaceuticals Inc’s debt, $0.18M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.25%, maturing 2031 to 2031.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Syndax Pharmaceuticals Inc and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Syndax Pharmaceuticals Inc's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Syndax Pharmaceuticals Inc's last four quarterly filings that the numbers alone won't show?”